Targeting Histone Deacetylases to Overcome Resistance of BRAFV600E Melanoma Cells to Apoptosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1026458

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Results from early clinical studies with a new class of drugs in the treatment of melanoma have been very encouraging, but most tumors initially respond to the drugs regrow after short periods. We have recently shown that this is mainly related to resistance of melanoma cells to cell death induced by the drugs. In this project, we aim to explore a novel approach to overcome this resistance. If successful, the results will lead to new approaches in the treatment of melanoma.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: NHMRC Project Grants

Funding Amount: $353,140.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer biology | histone deacetylase | kinase inhibitors | melanoma | signal transduction | targeted therapy

Related Links